TOKYO, Feb. 27, 2018 /Kyodo JBN-AsiaNet/ --
Genesis
Healthcare Co., Japan's pioneer genetic testing and research company,
has completed a third-party equity allocation to Rakuten, Inc. (TSE:
4755) and Omron Healthcare Co., Ltd. Genesis' Capital has increased to
3.78 billion yen, and Genesis' post-money valuation is approximately 42
billion yen (*1).
As the market leader in the genetic testing and
research field in Japan, Genesis has actively pursued development of
the Japanese scientific landscape through numerous R&D, product
development, awareness raising via human resource development and
advanced education, and genetic data translation into useful solutions.
As of today, the company's Japanese genetic data platform exceeds
550,000 individuals, the largest in Japan and potentially in Asia. In
2018, Genesis aims to accumulate data of 1 million people, or 1% of the
population in Japan.
This will be Rakuten's second investment
since its initial investment in August 2017. Rakuten's commitment to
assist in the development and advancement of genetic technology and its
useful applications in healthcare is a novel approach to fostering
innovation.
Secondly, Omron Healthcare and Genesis have formed a
partnership since 2014. Both companies jointly developed a personalized
health solution business model combining a genetic test kit from Genesis
and digital health wearables from Omron Healthcare. The new capital
will further strengthen the partnership as the addition of biometric
information such as blood pressure from Omron's precision wearable
devices will maximize the utility of Genesis' genetic data-sharing
platform. By analyzing various data, both Omron Healthcare and Genesis
will develop and provide services to predict in advance future severe
illness, treatment to prevent the onset of the disease, and guidance on
health management. Together, the two companies will work to promote and
realize ideal solutions for personalized healthcare.
(*1) The
equity value is based on the latest financing stock price of Omron
Healthcare Co., Ltd. multiplied by the total number of issued shares.
As
a leading company in the genetic field in Japan, Genesis will continue
to pursue the development of genetic research and tests in Japan and
then explore the market worldwide.
Genesis Healthcare website: http://genesis-healthcare.jp/en/
SOURCE: Genesis Healthcare Co.
No comments:
Post a Comment